Janus Henderson INVESTORS

HORIZON BIOTECHNOLOGY FUND

At a glance

Performance*
The Fund returned 0.51%, the Index returned 2.88% and the Sector returned −0.35%.

Contributors/detractors
Travere Therapeutics and Bicara Therapeutics were among the main detractors for the month, while BridgeBio Pharma and AstraZeneca were among the contributors.

Outlook
We believe the outlook for the biotech sector remains attractive, and we continue to favour small- and mid-cap biotech stocks with newly launched products or promising late-stage pipelines.

Portfolio management


Andy Acker, CFA


Daniel Lyons, Ph.D., CFA


Agustin Mohedas, Ph.D.

Investment environment

- An investor shift away from what we viewed as more speculative investments during October pushed small-cap biotechnology stocks lower, while larger-cap biotechs rose.
- The US Department of Health and Human Services released draft guidance to help advance personalised gene therapies for rare genetic diseases. Patient-specific therapy variants that meet established safety and efficacy parameters may be added to an existing biologics license application without requiring new clinical trials, which could potentially accelerate timelines for companies developing personalised gene-editing and rare-disease therapies.
- Drug approvals in October were highlighted by the approval of bepirovirsen, the first antisense therapy to demonstrate functional cure rates above those achieved with the current standard of care for chronic hepatitis B. Additionally, the first once-monthly subcutaneous injectable version of olanzapine for schizophrenia was approved, with the potential for improved compliance.
- Biopharma dealmaking remained active in October, with Alcon agreeing to acquire Neurotech Pharmaceuticals, adding its cell therapy platform and the only US Food and Drug Administration (FDA)-approved treatment for MacTel (Macular Telangiectasia Type 2), a rare, progressive retinal disease. Viatris announced a $1.65 billion acquisition of Pacira BioSciences to strengthen its non-opioid pain portfolio, while Japan-based Shionogi announced a $2 billion all-cash acquisition of IntraBio centred on the commercialisation of its treatment for rare neurodegenerative disorders.
- Initial public offering (IPO) activity picked up in October, highlighting renewed investor interest in innovative biotech platforms. This included Lycia Therapeutics, which develops protein-degrading therapies, and City Therapeutics, which also went public to support the development of its RNAi therapy targeting Factor XI for thrombosis prevention. Other notable offerings included Iambic Therapeutics, focused on accelerating its AI-driven oncology pipeline; TREX Bio, which is leveraging its platform to discover therapies that modulate regulatory T cells involved in inflammation; and Retension Pharmaceuticals, which is developing treatments for uncontrolled hypertension.

Portfolio review

Shares of Travere Pharmaceuticals fell even as the company presented new biomarker data at ASN Kidney Week suggesting that the firm's treatment, Filspari, may

Marketing communication
For professional investors only
Past performance does not predict future returns.
References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned. There is no guarantee that past trends will continue, or forecasts will be realised.
*For benchmark and sector, if applicable, refer to Fund details on page 3. For relevant descriptions, risks and the Fund's investment policy statement, refer to Additional fund information on page 4.

modify the underlying disease biology of IgA Nephropathy (IgAN) beyond its established effects on reducing blood pressure and proteinuria. While investors are closely tracking the launch of Filspari in its second indication, focal segmental glomerulosclerosis (FSGS), debate continues around the durability of Filspari's market share in IgAN as new therapies advance into the market. However, we believe the therapy is likely to remain a core component of the standard of care in IgAN and we see potential for significant growth ahead in FSGS. As a result, we viewed the recent share price weakness as a long-term opportunity.

Bicara Therapeutics, a company developing a treatment to improve tumour penetration in head and neck cancer, detracted. Its share price fell after a competing therapy reported positive phase 3 results, including improved overall survival in the same indication. We remain constructive on Bicara's prospects to offer benefits in this condition as the company releases pivotal data in the coming year.

BridgeBio Pharma was among the top contributors after reporting third-quarter revenue of $353 million, driven by US Attruby sales that exceeded consensus expectations. Attruby, which treats transthyretin amyloid cardiomyopathy (ATTR-CM), is expected by management to reach approximately $4 billion in peak annual sales. We also believe the market may be anticipating three new pipeline launches for Bridge over the coming year.

AstraZeneca also contributed, helped by a strong third-quarter earnings report alongside positive clinical data in oncology. Robust growth in the firm's core franchises, particularly from lung cancer therapy Tagrisso and immunotherapy, drove accelerated revenue growth. During the month, late-stage trial data for sonesitatug vedotin in advanced gastric cancer showed a 53% reduction in the risk of death among third-line and later patients, highlighting the strength of AstraZeneca's pipeline.

Manager outlook

Market performance in biotechnology diverged again in October, with many fundamentally strong biotechnology stocks lagging. However, underlying industry fundamentals remained constructive, in our view. Capital-raising activity was active, reflecting continued investor appetite for differentiated innovation despite higher interest rates and broader market volatility. Strategic partnership and licensing activity also continued as large pharmaceutical companies seek external innovation to strengthen pipelines ahead of significant patent expirations.

While the current environment has created a temporary headwind for the portfolio, we remain confident that disciplined stock selection, valuation awareness, and a focus on differentiated clinical innovation will be rewarded over the long term. As always, our investment process emphasises finding the next wave of medical breakthroughs with the potential to change the practice of medicine.

Performance (%)

Returns	Cumulative				Annualised			
	1 Month	3 Month	YTD	1 Year	3 Year	5 Year	10 Year	Since inception (10/12/18)
A2 USD (Net)	0.51	-2.98	10.75	22.36	31.23	14.26	—	19.08
Index	2.88	13.56	28.81	37.17	26.52	8.81	—	11.54
Sector	-0.35	4.75	15.13	20.88	21.59	3.84	—	7.46
A2 USD (Gross)	—	—	—	—	—	17.99	—	23.19
Target	—	—	—	—	—	10.99	—	13.77

Calendar year	YTD at Q3 2026	2025	2024	2023	2022	2021	2020	2019	2018 from 10 Dec
A2 USD (Net)	10.19	49.37	6.06	23.28	-3.78	-5.17	61.32	34.70	-7.50
Index	25.20	33.43	-0.57	4.59	-10.12	0.02	26.42	25.11	-6.85
Sector	15.54	33.69	-4.20	5.25	-17.17	-7.68	27.50	25.36	-7.02

Performance is on a net of fees basis, with gross income reinvested. Source: at 31/10/26. © 2026 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. **Past performance does not predict future returns.** Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period. **The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.** Source for target returns (where applicable) - Janus Henderson Investors.

Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at www.janushenderson.com.

Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.

Performance fees may be charged before the Fund's outperformance target is reached.

Performance fees are charged separately as a way of rewarding the investment manager for superior returns or for outperforming specified targets. A Performance Fee is accrued where the NAV outperforms the relevant Hurdle NAV (subject to a High Water Mark). For further explanation of the performance fee calculation methodology please see the relevant prospectus, available at www.janushenderson.com.

Investment objective

The Fund aims to provide capital growth over the long term. Performance target: To outperform the NASDAQ Biotechnology Total Return Index by 2% per annum, before the deduction of charges, over any 5 year period.

For the fund's investment policy, refer to the Additional fund information on page 4.
Past performance does not predict future returns.

Fund details

Inception date	10 December 2018
Total net assets	2.20bn
Asset class	Equities
Domicile	Luxembourg
Structure	SICAV
Base currency	USD
Index	NASDAQ Biotechnology Total Return Index
Morningstar sector	Sector Equity Biotechnology
SFDR category	Article 8

In accordance with the Sustainable Finance Disclosure Regulation, the Fund is classified as Article 8 and promotes, among other characteristics, environmental and/or social characteristics, and invests in companies with good governance practices.

Lower Risk 1 2 3 4 **5** 6 7 Higher Risk

Rating as at previous month end. Rating is for the representative share class as defined in the performance table.

Additional fund information

Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change. Please note the performance target is to be achieved over a specific annualised time period. Refer to the performance target wording within the objective. Availability of share classes shown may be limited by law in certain jurisdictions. Performance records/scenarios are detailed within the fund's specific KIID/KID; fees and charges, and the respective risk rating may vary. Further information can be found in the fund's prospectus and KIID/KID, which must be reviewed before investing. Please consult your local sales representative and/or financial adviser if you have any queries. This is a Luxembourg SICAV Fund, regulated by the Commission de Surveillance du Secteur Financier (CSSF). These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors or indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them. The information in this commentary does not qualify as an investment recommendation. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. Cash balances and exposures are based on settled and unsettled trades as at the reporting date.

Investment policy

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, of any size, including smaller capitalisation companies, in any country. The Fund may also invest in other assets including bonds (including convertible bonds), preference shares, cash and money market instruments. The Investment Manager may use derivatives (complex financial instruments) with the aim of making investment gains in line with the Fund's objective, to reduce risk or to manage the Fund more efficiently. The Fund is actively managed with reference to the NASDAQ Biotechnology Total Return Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target and the level above which performance fees may be charged (if applicable). The Investment Manager has discretion to choose investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

Investment strategy

The Investment Manager looks to identify innovative biotechnology companies addressing high unmet medical needs and trading at a significant discount to their intrinsic value. The portfolio may have a bias towards development stage companies. The team understands that success of drug development is binary in nature, creating wide disparities between winners and losers. The investment process leverages proprietary statistical models to analyse the probability of a company's success, focusing on products they believe can overcome the rigours of clinical development. Additional tools such as physician surveys, prescription models and scenario simulations attempt to more accurately predict commercial viability.

Fund specific risks

Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result. Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses. High exposure to a particular country or geographical region carries a higher level of risk than a more broadly diversified portfolio. The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events. If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. seeks to mitigate exchange rate movements between the share/unit class currency and the base currency of the Fund), the value of your investment may be impacted by changes in exchange rates. Derivatives may be used to help achieve the investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations. When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies. Securities could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses. The Fund may incur a higher level of transaction costs as a result of investing in less actively traded or less developed markets compared to a fund that invests in more active/developed markets. Losses could be incurred if a counterparty became unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider. The sustainability approach applied may exclude potential investments which do not meet certain criteria (e.g. non-financial criteria such as ESG screens). This may cause differences in performance compared to similar products that are permitted to invest in those investments.

Source for risk rating

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. We have classified this product as 5 out of 7, which is a medium-high risk class. The risk indicator assumes you keep the product for 5 years. This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact our capacity to pay you.

FOR MORE INFORMATION PLEASE VISIT **JANUSHENDERSON.COM**

Janus Henderson
INVESTORS

Source: Janus Henderson Investors, as at 31 October 2026, unless otherwise noted.

This document is intended solely for the use of professionals and is not for general public distribution. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions. Any investment application will be made solely on the basis of the information contained in the Fund's prospectus (including all relevant covering documents), which will contain investment restrictions. This document is intended as a summary only and potential investors must read the Fund's prospectus and key information document before investing. A copy of the Fund's prospectus and key information document can be obtained from Janus Henderson Investors UK Limited in its capacity as Investment Manager and Distributor. For sustainability related aspects please access Janushenderson.com. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. Past performance does not predict future returns. The performance data does not take into account the commissions and costs incurred on the issue and redemption of units. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor's particular circumstances and may change if those circumstances or the law change. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially. The securities included in this document are not registered in the Foreign Securities Registry of the Superintendencia de Valores y Seguros for public offering and, therefore, the use of this document is only

for general information purposes. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. The Fund is a recognised collective investment scheme for the purpose of promotion into the United Kingdom. Potential investors in the United Kingdom are advised that all, or most, of the protections afforded by the United Kingdom regulatory system will not apply to an investment in the Fund and that compensation will not be available under the United Kingdom Financial Services Compensation Scheme. With effect from 1 January 2023, the Key Investor Information document (KIID) changed to the Key Information Document (KID), except in the UK where investors should continue to refer to the KIID. The Janus Henderson Horizon Fund (the "Fund") is a Luxembourg SICAV incorporated on 30 May 1985, managed by Janus Henderson Investors Europe S.A. Issued by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), Tabula Investment Management Limited (reg. no. 11286661), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 78, Avenue de la Liberté, L-1930 Luxembourg, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier). Copies of the Fund's Prospectus, Key Information Document, Articles of Incorporation, annual and semi-annual reports are available in English and other local languages as required from www.janushenderson.com. These documents can also be obtained free of charge from the Registered Office of the Company at 78, Avenue de la Liberté, L-1930 Luxembourg, Luxembourg. They can also be obtained free of charge from the local Facilities Agents and the Swiss representative and paying agent. Janus Henderson Investors Europe S.A. ("JHIESA"), 78, Avenue de la Liberté, L-1930 Luxembourg, Luxembourg, is the Facilities Agent in Austria, Belgium Germany, Ireland, Malta, Portugal, Sweden and Liechtenstein. JHIESA is also the Facilities Agent for France (Sub – TA is CACEIS). FE fundinfo (Luxembourg) S.à.r.l., 6 Boulevard des Lumières, Belvaux, 4369 Luxembourg, is the Facilities Agent in Denmark, Finland, Iceland, Netherlands, Norway, Poland and Greece. State Street Bank International GmbH – Succursale Italia, Société Générale Securities Services S.p.A (SGSS S.p.A), Allfunds Bank S.A.U filiale di Milano, Caceis Bank Italy Branch, and Banca Sella Holding S.p.A. are the Sub Transfer Agents for Italy. Allfunds Bank S.A., Estafeta 6, La Moraleja, Complejo Plaza de la Fuente, Alcobendas 28109, Madrid, Spain is the Facilities Agent in Spain (Janus Henderson Horizon Fund is registered with the CNMV under number 353). The prospectus, the key information documents, the articles, the annual and semi-annual Reports as well as a list of all purchases and sales for the account may be obtained free of charge from the Swiss Representative. The Swiss Representative is FIRST INDEPENDENT FUND SERVICES LTD., Feldeggstrasse 12, CH-8008 Zurich. The Paying Agent in Switzerland is Banque Cantonale de Genève, 17, quai de l'Ile, CH-1204 Geneva. In respect of the units offered in Switzerland, the place of performance is the registered office of the representative. The place of jurisdiction is at the registered office of the representative or at the registered office or place of residence of the investor. The Hong Kong Representative is Janus Henderson Investors Hong Kong Limited of Units 701-702, 7/F, LHT Tower, 31 Queen's Road Central, Hong Kong. Janus Henderson Investors (Singapore) Limited (Company Registration No. 199700782N), whose principal place of business is at 138, Market Street #34-03/04, CapitaGreen, Singapore 048946, Singapore (Tel: 65 6813 1000). The summary of Investors Rights is available in English from https://www.janushenderson.com/summary-of-investors-rights-english. Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation. Janus Henderson® and any other trademarks used herein are trademarks of Janus Henderson Group Ltd. or one of its subsidiaries. © Janus Henderson Group Ltd.